Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Towa to Review Existing Products for Improved Competitiveness, Starting with 70 APIs
May 22, 2012
- Chugai to Make CNS Its Strategic Field; 3 Compounds in Pipeline: President Kosaka
May 21, 2012
- Operating Profits Up 4.2%, Business Expansion Slows Down in FY2011: Major Generics Manufacturers
May 21, 2012
- Hisamitsu Files for Transdermal Oxybutynin for Overactive Bladder
May 21, 2012
- The Growing Presence of Foreign-Affiliates (3)
May 21, 2012
- “Confident in Usefulness” of Alogliptin: President Hasegawa of Takeda
May 18, 2012
- Ono to Conduct Joint Research with German Pharmaceutical Company Using Affilin Technology
May 18, 2012
- Ishibashi to Become SSP President, Torii to Be Withdrawn from Presidency
May 18, 2012
- Morishita Jintan, AnGes MG Jointly Research and Develop Oral Vaccine
May 18, 2012
- Pfizer Resubmit NDA for Fesoterodine Fumarate in March
May 18, 2012
- Eisai Sets Domestic Sales Forecast for Aricept at 90 Billion Yen on Impact of Generics
May 17, 2012
- Double-Digit Drop in Sales, Profits Reported Due to Patent Expiration of Aricept: Eisai
May 17, 2012
- Nichi-Iko, sanofi-aventis to Copromote Lipitor Generic Aiming at Cumulative Sales of 10 Billion Yen over 5 Years
May 17, 2012
- Sawai Targets Sales of 100 Billion Yen in FY2014, Gives Up Biosimilars Development: New Midterm Plan
May 17, 2012
- FY2011 Settlement of Accounts: Second-Tier Drug Makers Struggled, Domestic-Focused Mid-Sized Makers Posted Growth
May 17, 2012
- Top Five Drug Makers Report 12.8% Decline in Operating Profits with 3 Reporting Double-Digit Falls in Profits
May 17, 2012
- Final Costs to Be Confirmed by Product, Changing from Manufacturer Basis: Medipal Group
May 16, 2012
- Pivotal Focus for Biosimilars Business on Japan: Daiichi Sankyo President Nakayama
May 16, 2012
- Vedolizumab Achieved Remission in Crohn’s Disease Patients in PIII: Takeda
May 16, 2012
- Eisai to Increase the Number of Representative Corporate Officers from 2 to 5
May 16, 2012
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…